Incyte Corporation  

(Public, NASDAQ:INCY)   Watch this stock  
Find more results for INCY
+2.09 (2.37%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 86.67 - 90.35
52 week 55.00 - 133.62
Open 88.52
Vol / Avg. 859,753.00/996,168.00
Mkt cap 16.81B
P/E 428.27
Div/yield     -
EPS 0.21
Shares 187.62M
Beta 0.77
Inst. own 99%
Aug 9, 2016
Q2 2016 Incyte Corp Earnings Call - 10:00AM EDT - Add to calendar
Aug 9, 2016
Q2 2016 Incyte Corp Earnings Release - 7:00AM EDT - Add to calendar
Jun 8, 2016
Incyte Corp at Goldman Sachs Global Healthcare Conference
Jun 8, 2016
Incyte Corp at Jefferies Healthcare Conference
May 27, 2016
Incyte Corp Annual Shareholders Meeting
May 23, 2016
Incyte Corp at UBS Global Healthcare Conference
May 20, 2016
Incyte Corp Annual Shareholders Meeting (Estimated)
May 11, 2016
Incyte Corp at Bank of America Merrill Lynch Health Care Conference - Webcast
May 9, 2016
Q1 2016 Incyte Corp Earnings Call - Webcast
May 9, 2016
ARIAD Pharmaceuticals Inc & Incyte Corp Announce Agreement for Incyte to Acquire ARIAD's European Operations and In-license Iclusig (ponatinib) in Europe Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 9.13% 0.87%
Operating margin 13.68% 6.72%
EBITD margin - 12.67%
Return on average assets 9.14% 0.72%
Return on average equity 48.36% 14.59%
Employees 692 -
CDP Score - -


1801 Augustine Cut off
WILMINGTON, DE 19803-4404
United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company's second oral JAK1 and JAK2 inhibitor is baricitinib.

Officers and directors

Herve Hoppenot Chairman of the Board, President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
David W. Gryska Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Reid M. Huber Executive Vice President, Chief Scientific Officer
Age: 44
Bio & Compensation  - Reuters
Eric H. Siegel Executive Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Paula J. Swain Executive Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Barry P. Flannelly Executive Vice President and General Manager , US
Age: 58
Bio & Compensation  - Reuters
Wenqing Yao Ph.D. Executive Vice President - Discovery Medicinal and Process Chemistry
Age: 53
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Director
Age: 73
Bio & Compensation  - Reuters
Jean-Jacques Bienaime Independent Director
Age: 62
Bio & Compensation  - Reuters